• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Cardiol Therapeutics Inc.

    5/29/25 7:30:12 AM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRDL alert in real time by email
    6-K 1 form6k.htm FORM 6-K Cardiol Therapeutics Inc.: Form 6-K - Filed by newsfilecorp.com

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2025

    Commission File Number: 001-40712

    Cardiol Therapeutics Inc.
    (Translation of registrant's name into English)

    602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    [   ] Form 20-F     [X] Form 40-F


    SUBMITTED HEREWITH

    Exhibits

    Exhibit   Description
       
    99.1   News Release dated May 29, 2025 - Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      CARDIOL THERAPEUTICS INC.
      (Registrant)
         
    Date: May 29, 2025 By: /s/ Chris Waddick
        Chris Waddick
      Title: Chief Financial Officer


    Get the next $CRDL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRDL

    DatePrice TargetRatingAnalyst
    1/28/2025$7.00Buy
    Rodman & Renshaw
    6/26/2024$10.00Buy
    ROTH MKM
    4/22/2024$9.00Buy
    H.C. Wainwright
    12/17/2021$8.00Overweight
    Cantor Fitzgerald
    12/3/2021$8.00Buy
    Canaccord Genuity
    More analyst ratings

    $CRDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cardiol Therapeutics Inc.

      SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)

      11/6/24 2:59:55 PM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cardiol Therapeutics Inc. (Amendment)

      SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)

      2/13/24 1:01:41 PM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cardiol Therapeutics Inc. (Amendment)

      SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)

      2/14/23 11:52:10 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDL
    Leadership Updates

    Live Leadership Updates

    See more
    • Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

      Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated April 10, 2025.Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: Jennifer Chao, David E

      5/29/25 7:27:00 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

      Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024.Resolutions proposed and approved at the Meeting were:The election of the following directors for the

      6/27/24 12:29:00 PM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiol Therapeutics Reports Results of 2023 Annual General Meeting

      Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2023. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular. Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: David Elsley, Peter Pekos, Dr. Gui

      6/29/23 10:19:00 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDL
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CRDL
    SEC Filings

    See more

    $CRDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

      Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated April 10, 2025.Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: Jennifer Chao, David E

      5/29/25 7:27:00 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

      Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on May 28, 2025, at 4:30 p.m. EDT.Cardiol Therapeutics' 2025 AGMWhen: May 28, 2025, at 4:30 p.m. EDTWhere: Virtual meeting only via live audio webcast online at: web.lumiagm.com/226536161Additional information about the AGM, including details on how to participate and vote, is available on the Company's website at card

      5/27/25 7:27:00 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

      Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experienceToronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to stand for election to the Company's Board of Directors at its 2025 Annual General Meeting of shareholders to be held on May 28, 2025.Dr. Garnett is a distinguished pharmaceutical industry executive with over 30 y

      4/29/25 7:27:00 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Cardiol Therapeutics Inc.

      6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)

      5/29/25 7:30:12 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Cardiol Therapeutics Inc.

      6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)

      5/27/25 7:29:20 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Cardiol Therapeutics Inc.

      6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)

      5/14/25 4:37:01 PM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Cardiol Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $7.00

      1/28/25 7:11:43 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ROTH MKM initiated coverage on Cardiol Therapeutics with a new price target

      ROTH MKM initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $10.00

      6/26/24 8:07:20 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Cardiol Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $9.00

      4/22/24 7:28:31 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care